Table of Contents
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
August 20, 2003 (August 18, 2003)
Date of Report (Date of earliest event reported)
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-28782 | 93-0979187 | ||
(State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||
157 Technology Drive Irvine, California | 92618 | |||
(Address of principal executive offices) | (Zip Code) |
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
Item 5. Other Events | ||||||||
Item 7. Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Table of Contents
Item 5. Other Events
On August 18, 2003, Spectrum Pharmaceuticals, Inc. (the “Company”) and Lannett Company, Inc. announced that they have entered into an exclusive supply, marketing and distribution agreement for ciprofloxacin.
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 7. Exhibits
Exhibits: | ||
99.1 | Press release dated August 18, 2003. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPECTRUM PHARMACEUTICALS, INC. | ||||
Date: August 20, 2003 | By: | /s/ Rajesh C. Shrotriya | ||
Name: Title: | Rajesh C. Shrotriya, M.D. Chairman, Chief Executive Officer and President |
2
Table of Contents
EXHIBIT INDEX
Exhibits: | ||
99.1 | Press release dated August 18, 2003. |